Patient-Friendly Explanation

Bimagrumab is an investigational injectable medicine being studied for weight loss. Unlike most weight-loss drugs that mainly reduce appetite, it acts on muscle and fat tissue to reduce body fat while helping to preserve muscle. It is not yet approved for routine clinical use.

Clinical Definition

Bimagrumab is a human monoclonal antibody that inhibits activin type II receptors (ActRII), blocking the negative regulators of skeletal muscle growth (myostatin and activin A). In clinical trials it has reduced fat mass while preserving or increasing lean mass, making it a promising investigational agent for obesity and sarcopenic obesity. It is administered intravenously and remains under investigation.

Why It Matters

A major challenge of weight loss is losing muscle along with fat. Agents such as bimagrumab that preserve lean mass could change how obesity is treated in the future. NuLifeCare Singapore tracks emerging therapies so patients can understand their options as the evidence evolves.